These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 2491941)

  • 41. Deprenyl in the management of response fluctuations in patients with Parkinson's disease on levodopa.
    Schachter M; Marsden CD; Parkes JD; Jenner P; Testa B
    J Neurol Neurosurg Psychiatry; 1980 Nov; 43(11):1016-21. PubMed ID: 6777463
    [TBL] [Abstract][Full Text] [Related]  

  • 42. (-)-Deprenyl, a selective MAO-B inhibitor, with apoptotic and anti-apoptotic properties.
    Magyar K; Szende B
    Neurotoxicology; 2004 Jan; 25(1-2):233-42. PubMed ID: 14697898
    [TBL] [Abstract][Full Text] [Related]  

  • 43. L-deprenyl plus L-phenylalanine in the treatment of depression.
    Birkmayer W; Riederer P; Linauer W; Knoll J
    J Neural Transm; 1984; 59(1):81-7. PubMed ID: 6425455
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Neuropsychological effects of L-deprenyl in Alzheimer's type dementia.
    Piccinin GL; Finali G; Piccirilli M
    Clin Neuropharmacol; 1990 Apr; 13(2):147-63. PubMed ID: 2109658
    [TBL] [Abstract][Full Text] [Related]  

  • 45. (-)Deprenyl-medication: a strategy to modulate the age-related decline of the striatal dopaminergic system.
    Knoll J
    J Am Geriatr Soc; 1992 Aug; 40(8):839-47. PubMed ID: 1634730
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The effect of various monoamine oxidase (MAO) inhibitors on the response of blood pressure of rats and cats to tyramine.
    Abdo-Rubo A
    Acta Physiol Hung; 1990; 75(4):321-36. PubMed ID: 2127505
    [TBL] [Abstract][Full Text] [Related]  

  • 47. N-propargylbenzylamine, a major metabolite of pargyline, is a potent inhibitor of monoamine oxidase type B in rats in vivo: a comparison with deprenyl.
    Karoum F
    Br J Pharmacol; 1987 Feb; 90(2):335-45. PubMed ID: 3103805
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Selegiline in Parkinson's disease.
    Teräväinen H
    Acta Neurol Scand; 1990 Apr; 81(4):333-6. PubMed ID: 2113756
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The pharmacological profile of (-)deprenyl (selegiline) and its relevance for humans: a personal view.
    Knoll J
    Pharmacol Toxicol; 1992 May; 70(5 Pt 1):317-21. PubMed ID: 1608919
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of long-term treatment with selective monoamine oxidase A and B inhibitors on dopamine release from rat striatum in vivo.
    Lamensdorf I; Youdim MB; Finberg JP
    J Neurochem; 1996 Oct; 67(4):1532-9. PubMed ID: 8858937
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Mechanism of inhibition by chlorgyline and deprenyl of tyramine deamination by mitochondrial monoamine oxidase of rat liver].
    Deverina IS
    Biokhimiia; 1980 Oct; 45(10):1897-908. PubMed ID: 6786369
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
    Chen JJ; Swope DM; Dashtipour K
    Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A new low-dose formulation of selegiline: clinical efficacy, patient preference and selectivity for MAO-B inhibition.
    Clarke A; Johnson ES; Mallard N; Corn TH; Johnston A; Boyce M; Warrington S; MacMahon DG
    J Neural Transm (Vienna); 2003 Nov; 110(11):1257-71. PubMed ID: 14628190
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The pharmacology of (-)deprenyl.
    Knoll J
    J Neural Transm Suppl; 1986; 22():75-89. PubMed ID: 3097262
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Possible mechanism of selective inhibition of rat liver mitochondrial monoamine oxidase by chlorgiline and deprenyl].
    Severina IS
    Biokhimiia; 1979 Feb; 44(2):195-207. PubMed ID: 435561
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Selegiline transdermal system in the prevention of relapse of major depressive disorder: a 52-week, double-blind, placebo-substitution, parallel-group clinical trial.
    Amsterdam JD; Bodkin JA
    J Clin Psychopharmacol; 2006 Dec; 26(6):579-86. PubMed ID: 17110814
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Double-blind trial of R-(-)-deprenyl for the "on-off" effect complicating Parkinson's disease.
    Golbe LI; Duvoisin RC
    J Neural Transm Suppl; 1987; 25():123-9. PubMed ID: 3123598
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Antidepressant potentiation of 5-hydroxytryptophan by L-deprenil in affective illness.
    Mendlewicz J; Youdim MB
    J Affect Disord; 1980 Jun; 2(2):137-46. PubMed ID: 6448885
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Selegiline ameliorates depression-like behaviors in rodents and modulates hippocampal dopaminergic transmission and synaptic plasticity.
    Ishikawa T; Okano M; Minami A; Tsunekawa H; Satoyoshi H; Tsukamoto Y; Takahata K; Muraoka S
    Behav Brain Res; 2019 Feb; 359():353-361. PubMed ID: 30359642
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Tranylcypromine compared with L-deprenyl in Alzheimer's disease.
    Tariot PN; Sunderland T; Cohen RM; Newhouse PA; Mueller EA; Murphy DL
    J Clin Psychopharmacol; 1988 Feb; 8(1):23-7. PubMed ID: 3127432
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.